Notice Regarding Recognition of an Extraordinary Loss (Impairment Loss on Software Development Costs, etc., Recognized Each Quarter)
VisasQ Inc.; consolidated subsidiary Coleman Research Group, Inc. (Coleman)
Software for customers and experts
Based on the business performance trends of Coleman, among other factors, the amount of capitalized software was recognized as an impairment loss.
Approximately ¥66 million (extraordinary loss and impairment loss)
The first quarter of the fiscal year ending February 2027, consolidated accounting period
The impairment loss was already reflected in the earnings forecast announced in April 2026 and will have no impact on the consolidated earnings forecast for the current fiscal year.
The Company intends to continue software development and other activities to support business growth, and expects related development costs to continue to arise.
| Item | Details |
|---|---|
| Event name | Notice Regarding Recognition of an Extraordinary Loss (Impairment Loss on Software Development Costs, etc., Recognized Each Quarter) |
| Subject Entity | VisasQ Inc.; consolidated subsidiary Coleman Research Group, Inc. (Coleman) |
| Target Locations / Products | Software for customers and experts |
| Cause | Based on the business performance trends of Coleman, among other factors, the amount of capitalized software was recognized as an impairment loss. |
| Amount of Impact on Business Performance | Approximately ¥66 million (extraordinary loss and impairment loss) |
| Accounting period in which recognized | The first quarter of the fiscal year ending February 2027, consolidated accounting period |
| Impact on Earnings Forecast | The impairment loss was already reflected in the earnings forecast announced in April 2026 and will have no impact on the consolidated earnings forecast for the current fiscal year. |
| Outlook | The Company intends to continue software development and other activities to support business growth, and expects related development costs to continue to arise. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Based on the business performance trends of consolidated subsidiary Coleman Research Group, Inc., among other factors, development costs and other amounts capitalized as software under US GAAP were recognized as an impairment loss.